EGFR and non-small cell lung carcinoma: A previous meta-analyses on gefitinib and erlotinib indicated that EGFR-TKI-associated rash may serve as a clinical marker for predicting the effective treatment response to EGFR-TKIs in NSCLC patients, including objective response rate (ORR) and disease control rate (DCR).